We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Postmarket Registry for Evaluation of the Superion® Spacer (PRESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04087811
Recruitment Status : Completed
First Posted : September 12, 2019
Last Update Posted : April 1, 2021
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
To gather evidence documenting the performance and clinical outcomes associated with treatment of moderate degenerative lumbar spinal stenosis using the Superion® Indirect Decompression System (IDS).

Condition or disease Intervention/treatment
Lumbar Spinal Stenosis Device: Superion® Indirect Decompression System (IDS)

Detailed Description:
To gather evidence documenting the performance and clinical outcomes associated with treatment of moderate degenerative lumbar spinal stenosis using the Superion® IDS in patients ≥45 years of age suffering from symptoms of neurogenic intermittent claudication secondary to a confirmed diagnosis of moderate degenerative lumbar spinal stenosis at one or two contiguous levels from L1 to L5.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1674 participants
Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Postmarket Registry for Evaluation of the Superion® Spacer
Actual Study Start Date : November 28, 2016
Actual Primary Completion Date : March 1, 2021
Actual Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Spinal Stenosis

Group/Cohort Intervention/treatment
Superion® Indirect Decompression System (IDS)
Superion® Indirect Decompression System (IDS) - Interspinous Spacer
Device: Superion® Indirect Decompression System (IDS)
Superion® Indirect Decompression System (IDS) (Superion® implant)




Primary Outcome Measures :
  1. Vertiflex® Patient Satisfaction Survey [ Time Frame: 3 Week Follow-Up Visit ]
    A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome

  2. Vertiflex® Patient Satisfaction Survey [ Time Frame: 6 Month Follow-Up Visit ]
    A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome

  3. Vertiflex® Patient Satisfaction Survey [ Time Frame: 12 Month Follow-Up Visit ]
    A score of ≥3 in each questionnaire component will be deemed a clinically meaningful outcome

  4. Visual Analogue Scale (VAS), Back and Leg Pain [ Time Frame: Pre-Operative Assessment, 3 Week, 6 Month and 12 Month Follow-Up Visit ]
    A change of 20 mm (on a 100 mm scale) from baseline is considered a clinically meaningful outcome

  5. Achievement of Self-Defined Functional Objective [ Time Frame: Pre-Operative Assessment, 3 Week, 6 Month and 12 Month Follow-Up Visit ]
    A change of ≥3 is considered evidence of significant improvement in function



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients suffering from symptoms of neurogenic intermittent claudication secondary to a confirmed diagnosis of moderate degenerative lumbar spinal stenosis
Criteria

Inclusion Criteria:

  • male and female patients ≥45 years of age
  • symptoms of neurogenic intermittent claudication and a confirmed diagnosis of moderate degenerative lumbar stenosis at one or two contiguous levels from L1 to L5
  • meeting the labeled indications for use of the Superion® Indirect Decompression System (IDS)

Exclusion Criteria:

  • not contraindicated as described in the labeled indications for use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04087811


Locations
Show Show 66 study locations
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Layout table for investigator information
Study Director: Roshini Jain Boston Scientific Corporation
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT04087811    
Other Study ID Numbers: 16-VISS-01
First Posted: September 12, 2019    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Boston Scientific Corporation:
LSS
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Stenosis
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases